CompletedPhase 2NCT02726503

Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer

Studying Anaplastic thyroid carcinoma

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Principal Investigator: Iwao Sugitani, M.D., Ph.D
Graduate School of Medicine Nippon Medical School
Intervention: Lenvatinib(drug)
Enrollment: 39 enrolled
Eligibility: 20 years · All sexes
Timeline: 2016 – 2020

Study locations (23)

Nagoya University Hospital, Nagoya, Aichi-ken, Japan
Fujita Health University Hospital, Toyoake, Aichi-ken, Japan
IUHW Ichikawa Hospital, Ichikawa, Chiba, Japan
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Japanese Red Cross Narita Hospital, Narita, Chiba, Japan
Kuma Hospital, Kobe, Hyōgo, Japan
Kobe Univbersity Hospital, Kobe, Hyōgo, Japan
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
Iwate Medical University Hospital, Morioka, Iwate, Japan
Kitasato University Hospital, Sagamihara, Kanagawa, Japan
Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
Miyaghi Cancer Center, Natori-shi, Miyagi, Japan
Tohoku University Hospital, Sendai, Miyagi, Japan
Shinsyu University School of Medicine Department of Surgery, Matsumoto, Nagano, Japan
+8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02726503 on ClinicalTrials.gov

Other trials for Anaplastic thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic thyroid carcinoma →

← Back to all trials